Showing results (161-170 of 261) with videos related to
Sort By:
Pageof 27
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.Plos One|November 7, 2014
The dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in miceGraeme I Lancaster, Michael J Kraakman, Helene L Kammoun, et al.The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.Lancet (London, England)|July 2, 1977
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysisD B Silk, P N Trewby, R A Chase, et al.The New Zealand Medical Journal|March 11, 1992
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemeticsP L Mitchell, B D Evans, S G Allan, et al.The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.Dermatology and Therapy|January 17, 2023
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled StudyAkihiko Asahina, Yukari Okubo, Akimichi Morita, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.Hepatology (Baltimore, Md.)|December 1, 1996
Pilot-controlled trial of the extracorporeal liver assist device in acute liver failureA J Ellis, R D Hughes, J A Wendon, et al.Pageof 27